SciELO - Scientific Electronic Library Online

 
vol.28 número3Gestão e plano de contingência do Serviço de Imunoalergologia do Centro Hospitalar e Universitário de S. João no contexto da pandemia por COVID-19 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Portuguesa de Imunoalergologia

versión impresa ISSN 0871-9721

Resumen

RODOLFO, Ana; FRIOES, Fernando  y  CERNADAS, Josefina R.. Immediate hypersensitivity to an emergency drug - New successful amiodarone dessensitization protocolo. Rev Port Imunoalergologia [online]. 2020, vol.28, n.3, pp.173-175. ISSN 0871-9721.  https://doi.org/10.32932/rpia.2020.09.041.

A 71-year-old male was admitted to the emergency room for dyspnea, thoracic pain and palpitations, where he was diagnosed with atrial flutter (AFL) with rapid ventricular rate (RVR), and was treated with bisoprolol, digoxine and verapamil. Because the RVR persisted, an amiodarone perfusion was started, during which an immediate episode of generalized urticaria occurred. The patient had a history of urticaria during an infusion of amiodarone in a previous episode of AFL with RVR. Although he was already medicated with digoxin and bisoprolol, he was still at high risk of RVR. Due to the reproducible immediate reactions to amiodarone, and the fact that amiodarone was the only therapeutic option, a 13-step desensitization protocol was designed, starting with an initial dose of 0.03 mg/mL (1/10 000 of the target cumulative dose) and ending with a final dose of 300 mg. The desensitization was successfully performed, without any immediate or late reactions. Then, a 200 mg oral daily dose was kept in order to maintain the desensitization state.

Palabras clave : Amiodarone; drug desensitization; emergency drug allergy.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons